Current role
Karen A. Cashmere
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Karen A. Cashmere
The proxy statement of ZyVersa Therapeutics, Inc. reports total compensation of $486,687 for Karen A. Cashmere in fiscal 2023, including a base salary of $320,000. Disclosed compensation is on record for 2 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
ZyVersa Therapeutics, Inc. (ZVSA)
Proxy statement
CurrentStart not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at ZyVersa Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Stephen C. Glover CEO, Board Member
- Peter Wolfe CFO
- Daniel J. O'Connor Board Member
- Gregory Freitag Board Member
- James Sapirstein Board Member
- Katrin Rupalla Board Member
- Min Chul Park, Ph.D. Board Member
- Min-Chul Park Board Member
- Rob G. Finizio Board Member
- Robert Finizio Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | ZyVersa Therapeutics, Inc. (ZVSA) | Chief Commercial Officer | $320,000 | $486,687 |
| 2022 | ZyVersa Therapeutics, Inc. (ZVSA) | Chief Commercial Officer | $300,000 | $582,622 |
Recent activity
No call appearances or filed executive changes recorded yet.